The U.S. Food and Drug Administration has approved Boehringer Ingelheim’s Jascayd (nerandomilast), a novel oral therapy for idiopathic pulmonary fibrosis (IPF), a rare and fatal lung disease. Jascayd, a twice-daily pill, works by inhibiting inflammatory proteins implicated in disease progression. While it does not cure IPF, clinical trials demonstrated Jascayd's ability to slow disease advancement, representing the first new IPF drug approval in over a decade. This approval introduces a critical option in a limited therapeutic landscape for IPF patients.